CULVER CITY, Calif.--(BUSINESS WIRE)--Oct. 3, 2016--
NantKwest, Inc (Nasdaq:NK), a pioneering, next generation,
clinical-stage immunotherapy company focused on harnessing the unique
power of the immune system using natural killer (NK) cells to treat
cancer, infectious diseases and inflammatory diseases, today announced
that the company has been selected to present at NK2016, the 16th
Annual Meeting of the Society for Natural Immunity in Taormina, Italy on
October 2nd – 5th, 2016.
The Society of Natural Immunity was established as an educational not
for profit organization in 1989 for the purpose of providing a framework
for supporting an established tradition of meetings and symposia on all
aspects of Natural Killer cells. “We have been a participant in the
Annual Meeting of the Society for Natural Immunity for many years.
Continuing our focus on harnesses the innate immune system through
natural killer cell based therapy, we are honored to be selected as a
presenter at the upcoming NK2016 conference,” said Dr. Hans Klingemann,
Vice President of Research and Development at NantKwest.
NantKwest’s presentations at NK2016 include the following:
Optimizing Allogeneic Natural Killer Cell Reactivity by Gene
Knock-Out/Knock-Down of Inhibitory Receptor. Presenter, Dr. Francisco
Navarro, NantKwest’s Senior Scientist.
Creating NK Cell Therapeutics with Multiple Targeting Activities:
Electroporation of MRNA for Chimeric Antigen Receptors (CARs) Into Human
NK Effector Cell Lines. Presenter, Dr. Junaid Khan, NantKwest’s Senior
Intra-Tumor Injection of CAR Engineered NK Cells Induces Tumor
Regression and Protection Against Tumor Re-Challenge. Presenter, Dr.
Laurent Boissel, NantKwest’s Associate Director of R&D.
About NantKwest Inc.
NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage
immunotherapy company focused on harnessing the unique power of our
immune system using natural killer (NK) cells to treat cancer,
infectious diseases and inflammatory diseases. NK cells are the body’s
first line of defense due to the innate ability of NK cells to rapidly
identify and destroy cells under stress, such as cancer or
NantKwest’s unique NK cell-based platform, with the capacity to grow
active killer cells as a biological cancer therapy, has been designed to
induce cell death against cancer or infected cells by three different
modes of action: (1) Direct killing using activated NK cells (aNK) that
release toxic granules directly into the cell through cell to cell
contact, (2) Antibody-mediated killing using haNKs, which are NK cells
engineered to incorporate a high affinity receptor that binds to an
administered antibody, enhancing the cancer cell killing effect of that
antibody, and (3) Targeted activated killing using taNKs, which are NK
cells engineered to incorporate chimeric antigen receptors (CARs) to
target tumor-specific antigens found on the surface of cancer cells.
Our aNK, haNK and taNK platform addresses certain limitations of T cell
therapies including the reduction of risk of serious "cytokine storms"
reported after T cell therapy. As an “off-the-shelf” therapy,
NantKwest's NK cells do not rely on a patient’s own often compromised
immune system. In Phase 1 clinical trials in patients with late stage
cancer, NantKwest's NK cells have been successfully administered as an
outpatient infusion therapy without any reported severe side effects,
even at doses of 10 billion cells.
By leveraging an integrated and extensive genomics and transcriptomics
discovery and development engine, together with a pipeline of multiple,
clinical-stage, immuno-oncology programs that include a Phase 2 trial
for a rare form of melanoma and the planned initiation of a clinical
trial of NK cells targeted to breast cancer, we believe NantKwest is
uniquely positioned to be the premier immunotherapy company and
transform medicine by delivering living drugs in a bag and bringing
novel NK cell-based therapies to routine clinical care. For more
information, please visit http://www.nantkwest.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161003005529/en/
Source: NantKwest, Inc
Jen Hodson, 562-397-3639